title: [Respiratory effects of chronic therapy with latanoprost in patients with chronic obstructive pulmonary disease (COPD)].
abstract: OBJECTIVE
  To study the respiratory effects of chronic therapy with latanoprost in Chronic Obstructive Pulmonary Disease (COPD) patients.
  
  
  METHODS
  We prospectively performed a spirometry in 19 COPD patients treated with latanoprost for more than 3 months, and the same masked-examiner repeated the test, under the same conditions, one week after latanoprost wash-out.
  
  
  RESULTS
  We found that latanoprost withdrawal increased forced espiratory volume (FEV1) (litre) from 1.5 S.D. 0.5 to 1.6 S.D. 0.5 and FEV1/FVC (forced vital capacity) index from 64.4 S.D. 8.6% to 66.5 S.D. 7.7% (both comparisons p=0.02, Wilcoxon signed-rank test).
  
  
  CONCLUSIONS
  Chronic therapy with latanoprost seems to induce a mild, though statistically significant, bronchoconstriction in COPD patients.
authors.affiliation: Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, España. esther-arranz@ole.com
authors.forename: E
authors.initials: E
authors.lastname: Arranz Márquez
authors.forename: M A
authors.initials: MA
authors.lastname: Teus Guezala
authors.forename: F
authors.initials: F
authors.lastname: Canseco González
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000494:pharmacology*; D005260:Female; D006801:Humans; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology*; D029424:Pulmonary Disease, Chronic Obstructive / Q000503:physiopathology*; D012119:Respiration / Q000187:drug effects*
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost